

Date: 22<sup>nd</sup> May, 2020

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Tower, Dalal Street,  
Fort, Mumbai - 400 001

Dear Sir/Madam,

**Sub: Outcome of Board Meeting**

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia approved:

1. Audited Financial Results for the quarter and financial year ended 31<sup>st</sup> March, 2020.

We enclose herewith the following:

- a) (i) Consolidated Audited Financial Results for the quarter and financial year ended 31<sup>st</sup> March, 2020.  
(ii) Consolidated Statement of Assets and Liabilities as at 31<sup>st</sup> March, 2020.  
(iii) Consolidated Cash Flow Statement for the financial year ended 31<sup>st</sup> March, 2020.
- b) (i) Standalone Audited Financial Results for the quarter and financial year ended 31<sup>st</sup> March, 2020.  
(ii) Standalone Statement of Assets and Liabilities as at 31<sup>st</sup> March, 2020.  
(iii) Standalone Cash Flow Statement for the financial year ended 31<sup>st</sup> March, 2020.
- c) Auditor's Report on Consolidated and Standalone Financial Results.

We hereby declare that the Statutory Auditors of the Company, M/s. K. S. Aiyar & Co., has issued audit report with unmodified opinion on the Consolidated and Standalone Audited Financial Results of the Company for the financial year ended 31<sup>st</sup> March, 2020. This declaration is given in compliance with Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**ALEMBIC PHARMACEUTICALS LIMITED**

2. The notice of Annual General Meeting which includes considering an enabling resolution for proposing to the members of the Company, raising of funds upto Rs. 1,200 Crores by way of issue of equity shares / other securities convertible into equity shares through Qualified Institutions Placement, as may be required by the Company from time to time. The fund raising is subject to necessary permissions and approvals (including shareholders' approval and such other statutory approvals as may be required) and the provisions of applicable law.

The time of commencement of the Board Meeting was 11:30 a.m. and the time of conclusion was 1:30 p.m.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

**For Alembic Pharmaceuticals Limited**



**Charandeep Singh Saluja**  
**Company Secretary**

Encl.: A/a.



**Statement of Consolidated Audited Financial Results for the quarter and year ended 31st March, 2020.**

Rs. in Crores

	Particulars	Quarter Ended			Year Ended	
		31.03.2020 (Audited)	31.12.2019 (Unaudited)	31.03.2019 (Audited)	31.03.2020 (Audited)	31.03.2019 (Audited)
1	<b>Revenue from Operations</b>	<b>1,206.83</b>	1,209.13	926.95	<b>4,605.75</b>	3,934.68
2	<b>Other Income</b>	<b>0.89</b>	0.41	3.37	<b>4.94</b>	9.38
3	<b>Total Income</b>	<b>1,207.72</b>	1,209.54	930.32	<b>4,610.69</b>	3,944.06
4	<b>Expenses</b>					
	(a) Cost of Materials consumed	<b>273.83</b>	233.44	206.84	<b>979.05</b>	850.04
	(b) Purchase of stock-in-trade	<b>34.99</b>	58.76	68.53	<b>270.93</b>	234.93
	(c) Changes in Inventories of finished goods, Stock in trade and WIP	<b>(44.93)</b>	6.29	(58.63)	<b>(210.59)</b>	(92.27)
	(d) Employee benefits expense	<b>246.92</b>	226.90	200.74	<b>906.44</b>	746.69
	(e) Finance Costs	<b>7.75</b>	7.36	5.08	<b>27.16</b>	18.41
	(f) Depreciation & Amortization Expense	<b>44.14</b>	41.82	29.95	<b>157.32</b>	115.23
	(g) Other Expenses	<b>368.50</b>	358.68	331.43	<b>1,436.89</b>	1,321.71
	<b>Total Expenses</b>	<b>931.20</b>	933.26	783.94	<b>3,567.22</b>	3,194.74
5	<b>Profit before exceptional items and tax</b>	<b>276.52</b>	276.28	146.38	<b>1,043.47</b>	749.32
6	<b>Less : Exceptional Items</b>					
	Expenses	<b>46.28</b>	-	-	<b>79.06</b>	-
	Incomes	<b>(35.42)</b>	-	-	<b>(35.42)</b>	-
7	<b>Profit before tax</b>	<b>265.66</b>	276.28	146.38	<b>999.82</b>	749.32
8	<b>Tax Expense</b>					
	(i) Current Tax	<b>47.29</b>	54.48	36.30	<b>204.57</b>	178.14
	(ii) Deferred Tax	<b>15.94</b>	(5.88)	(17.29)	<b>(4.30)</b>	(17.29)
	(iii) Short / (Excess) Tax Provision	<b>(1.09)</b>	-	(4.11)	<b>(1.09)</b>	(4.10)
9	<b>Profit for the Period before Share of Profit / (Loss) of Associates and Joint Ventures</b>	<b>203.52</b>	227.68	131.48	<b>800.64</b>	592.57
10	Share of Profit / (Loss) of Associates & Joint Venture	<b>(0.07)</b>	(0.37)	(7.78)	<b>0.05</b>	(9.28)
11	<b>Net Profit after taxes and Share of Profit / (Loss) of Associates and Joint Ventures but before non-controlling interests</b>	<b>203.45</b>	227.31	123.70	<b>800.70</b>	583.29
12	Non-controlling interests	<b>21.18</b>	6.88	0.30	<b>28.12</b>	1.08
13	<b>Net Profit after taxes, non-controlling interests and share of Profit / (Loss) of Associates and Joint Ventures</b>	<b>224.63</b>	234.19	124.00	<b>828.82</b>	584.37
14	<b>Other Comprehensive Income</b>					
	<b>A</b> (i) Items that will not be reclassified to profit / (loss)	<b>(7.34)</b>	2.35	(0.88)	<b>(11.42)</b>	(2.46)
	(ii) Income tax relating to items that will not be reclassified to profit / (loss)	<b>1.26</b>	(0.40)	0.19	<b>1.97</b>	0.53
	<b>B</b> (i) Items that will be reclassified to profit / (loss)	<b>3.51</b>	0.28	(0.76)	<b>7.64</b>	7.76
	<b>Total Other Comprehensive Income (A+B)</b>	<b>(2.58)</b>	2.23	(1.45)	<b>(1.82)</b>	5.83
15	<b>Total Comprehensive Income for the period (11+14)</b>	<b>200.87</b>	229.54	122.25	<b>798.88</b>	589.12
	<b>Attributable to:</b>					
	- Non-controlling interests	<b>(21.20)</b>	(6.88)	(0.31)	<b>(28.17)</b>	(1.09)
	- Owners of the Company	<b>222.08</b>	236.41	122.56	<b>827.05</b>	590.21
16	Earnings per share - Basic & Diluted (in Rs.)	<b>11.92</b>	12.42	6.58	<b>43.97</b>	31.00
17	Paid up Equity Share Capital (Face Value of Rs 2/- each)	<b>37.70</b>	37.70	37.70	<b>37.70</b>	37.70
18	Other Equity				<b>3,181.71</b>	2,681.12
19	Networth (17+18)				<b>3,219.41</b>	2,718.82
20	Debt Equity Ratio				<b>0.54</b>	0.42
21	Debt Service Coverage Ratio				<b>3.31</b>	9.77
22	Interest Service Coverage Ratio				<b>9.30</b>	9.77



**Notes :**

1 The above consolidated results, have been audited by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.

2 As additional information to investors, the Research and Development Expenses are provided here under:

Particulars	Quarter Ended			Year Ended	
	31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019
Research and Development	185.00	145.73	119.74	644.82	498.16

3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.

4 Asset cover available : - N.A. as unsecured non-convertible debentures were issued.

5 Next due date for payment of interest on unsecured non-convertible debentures is as follows, no principal amount is due till 31st March, 2021.

Particulars	Due date	Rs. in Crores
		Interest
Tranche I	3 <sup>rd</sup> December, 2020	13.28
Tranche II	14 <sup>th</sup> December, 2020	18.00
Tranche III	19 <sup>th</sup> March, 2021	12.56

6 Previous due date for payment of interest on unsecured non-convertible debentures is as follows, no principal amount was due. Interest have been paid on the due dates.

Particulars	Due date	Rs. in Crores
		Interest
Tranche I	9 <sup>th</sup> December, 2019	13.22
Tranche II	14 <sup>th</sup> December, 2019	18.00
Tranche III	19 <sup>th</sup> March, 2020	12.56

7 The Company is rated by leading credit agency CRISIL. The rating "AA+/Stable" and "CRISIL A1+" has been assigned for long term and short term facility respectively.

8 Debenture Redemption Reserve Rs. 83.33 Crores is included in Other Equity (point no 18).

9 Ratios:

a) Debt to Equity: Debt / Net Worth

Debt : Total Debt ( Short term + Long term)

Net worth : Share Capital + Other Equity

b) Debt Service Coverage Ratio: EBIT / (Interest on term & working capital debt + Principal repayments of Long term debt)  
(EBIT : Profit before Taxes + Interest)

c) Interest Service Coverage Ratio : EBIT / Interest

10 The Board of Directors had at their meeting on 6th March, 2020 declared Interim Dividend of Rs. 7/- (350%) per equity share and an additional Special Dividend of Rs. 3/- (150%) per equity share aggregating to total Interim Dividend of Rs. 10/- (500%) per equity share having face value of Rs. 2/- each for the financial year 2019-20 as against the Final Dividend of Rs. 5.50 (275%) per equity share for the financial year 2018-19. The same has been paid on 20th March, 2020 to the equity shareholders of the Company whose names appear in the Register of Members on 17th March, 2020, being the Record Date fixed for the purpose.

11 Effective 1st April, 2019, the Group has adopted Ind As 116 Leases using the modified retrospective approach. This has resulted in recognizing lease liability and equal amount of right of use assets as on 1st April, 2019. The adoption of the standard did not have any material impact on the financial results.

12 Exceptional items relates to impairment provision on investment in and loan given to Joint Venture namely Alembic Mami Algeria held by wholly owned subsidiary of the company Rs. 69.06 Crs, compensation to National Green Tribunal Rs. 10 Crs and write back of certain provisions, refund by vendor for non performance and settlement of Rs. 35.42 Crs.

13 As assessed by the management, Impact of Covid 19 on the financial statements of the Company is likely to be modest and for short term. Management does not foresee any medium to long term risk in company's ability to continue as going concern.

14 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / period.

**For Alembic Pharmaceuticals Limited**

CHIRAYU  
RAMANBHAI  
AMIN

Digitally signed by  
CHIRAYU RAMANBHAI  
AMIN  
Date: 2020.05.22  
13:30:53 +05'30'

**Chirayu Amin**  
Chairman and CEO

Place : Vadodara  
Date : 22nd May, 2020

Visit us at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com)



Alembic Pharmaceuticals Limited

Statement of Assets and Liabilities - Consolidated

Rs. in Crores

Particulars	As at 31st March, 2020 (Audited)	As at 31st March, 2019 (Audited)
<b>A ASSETS</b>		
<b>1 Non-current assets</b>		
(a) Property, plant and equipment	1,524.90	1,098.41
(b) Capital work-in-progress	1,574.10	1,341.40
(c) Goodwill	-	3.61
(d) Other Intangible assets	26.94	56.43
(e) Intangible assets under development	272.08	209.83
(f) Financial Assets :-		
(i) Investments	0.45	0.45
(ii) Investment accounted for using Equity Method	17.17	48.31
(g) Other non-current assets	110.66	61.59
<b>2 Current assets</b>		
(a) Inventories	1,187.53	967.26
(b) Financial Assets		
- Trade receivables	864.75	488.89
- Cash and Bank Balance	71.84	199.07
- Bank balances other than cash and cash equivalents	8.91	6.55
- Other financial assets	8.65	9.10
(c) Current Tax Assets (Net)	30.98	-
(d) Other current assets	290.08	286.86
<b>TOTAL - ASSETS</b>	<b>5,989.05</b>	<b>4,777.76</b>
<b>B EQUITY AND LIABILITIES</b>		
<b>1 Equity</b>		
(a) Equity Share capital	37.70	37.70
(b) Other Equity	3,181.71	2,681.12
(c) Non-controlling interests	3,219.41	2,718.82
	(28.96)	(0.78)
<b>Total Equity</b>	<b>3,190.45</b>	<b>2,718.04</b>
<b>2 Non-current liabilities</b>		
(a) Financial liabilities		
- Borrowings	886.99	499.30
- Others	73.30	-
(b) Provisions	74.51	52.03
(c) Deferred tax liabilities (net)	12.19	18.75
<b>3 Current liabilities</b>		
(a) Financial liabilities		
- Borrowings	860.50	429.13
- Trade payables		
A) Due to Micro and Small Enterprises	7.11	5.09
B) Due to other than Micro and Small Enterprises	618.82	639.25
- Other financial liabilities	121.92	292.19
(b) Other current liabilities	105.06	87.97
(c) Provisions	38.19	32.39
(d) Current tax liabilities	-	3.61
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>5,989.05</b>	<b>4,777.76</b>

For Alembic Pharmaceuticals Limited

CHIRAYU  
RAMANBHAI  
AMIN  
Digitally signed by  
CHIRAYU RAMANBHAI  
AMIN  
Date: 2020.05.22 13:31:30  
+05'30'

Place : Vadodara  
Date : 22nd May, 2020

Chirayu Amin  
Chairman and CEO

Visit us at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com)



Consolidated Cash Flow Statement for the year ended 31st March, 2020.

Particulars	Rs. In Crores	
	For the year ended 31st March, 2020 (Audited)	For the year ended 31st March, 2019 (Audited)
<b>A CASH FLOW FROM OPERATING ACTIVITIES:</b>		
Net Profit before tax after exceptional item	999.82	749.32
Adjustments for:		
Depreciation and amortisation	157.32	115.23
Interest charged	27.16	18.41
Interest Income	(1.73)	(2.58)
Dividend Income /Gain on Sale of Investments	(0.93)	(2.12)
Unrealised foreign exchange gain (net)	15.95	(23.83)
Provision / write off for doubtful trade receivables	8.55	16.69
Impairment goodwill and other intangible assets	53.71	-
Impairment in value of investments, net	33.65	-
Sundry balances written Back (net)	(2.82)	(0.58)
Remeasurement of Defined benefit obligations	(11.42)	(2.47)
Loss/(Profit) on sale of Asset	(1.16)	(1.18)
<b>Operating Profit before change in working capital</b>	<b>1,278.09</b>	<b>866.88</b>
Working capital changes:		
(Increase) In Inventories	(220.27)	(233.33)
(Increase)/Decrease In Trade Receivables	(358.26)	36.19
(Increase)/Decrease In Other Assets	(18.95)	175.13
(Decrease) In Trade Payables	(21.11)	(50.31)
Increase /(Decrease) In Other Liabilities	(2.52)	177.09
Increase In Provisions	28.27	6.79
<b>Cash generated from operations</b>	<b>685.24</b>	<b>978.45</b>
Direct taxes paid (Net of refunds)	(236.11)	(166.48)
<b>Net Cash inflow from Operating Activities (A)</b>	<b>449.13</b>	<b>811.96</b>
<b>B CASH FLOW FROM INVESTING ACTIVITIES:</b>		
Sales of Property, Plant & Equipments	0.60	1.28
Government assistance	-	17.15
Interest received	1.73	2.58
Dividend /Gain on Sale of Investments received	0.93	2.12
Purchase of Property, Plant & Equipments and Capital Advance	(672.65)	(653.93)
Investment in Associate	-	(14.36)
Intangible assets under development	(62.25)	(110.44)
<b>Net Cash inflow from Investing Activities (B)</b>	<b>(731.63)</b>	<b>(755.60)</b>



Particulars	For the year ended 31st March, 2020 (Audited)	For the year ended 31st March, 2019 (Audited)
<b>C CASH FLOW FROM FINANCING ACTIVITIES:</b>		
Proceeds from borrowings	378.02	603.70
Repayment of borrowings	(200.00)	(604.39)
Net increase / (decrease) in working capital demand loans	431.37	221.35
Payment of lease liabilities	(17.49)	-
Increase in Restricted Bank Balances other than Cash & Cash Equivalents	(0.02)	(0.38)
Dividends paid (including distribution tax)	(325.97)	(90.91)
Interest and other finance costs (including borrowing cost capitalised)	(111.06)	(70.34)
<b>Net Cash inflow from Financing Activities (C)</b>	<b>154.85</b>	<b>59.04</b>
<b>I Net (decrease)/increase in cash and cash equivalents (A+B+C)</b>	<b>(127.64)</b>	<b>115.40</b>
<b>II. a) Cash and cash equivalents at the beginning of the Year</b>	<b>199.07</b>	<b>83.74</b>
<b>b) Effect of exchange differences on restatement of foreign currency cash and cash equivalents</b>	<b>0.41</b>	<b>(0.07)</b>
<b>III. Cash and cash equivalents at the end of the Year (I+II)</b>	<b>71.84</b>	<b>199.07</b>
<b>IV. Cash and cash equivalents at the end of the Year</b>		
Balances with Banks	71.48	198.84
Cash on hand	0.36	0.23
Cash and cash equivalents	71.84	199.07

**For Alembic Pharmaceuticals Limited**

CHIRAYU  
RAMANBHAI AMIN  
AI AMIN

Digitally signed by  
CHIRAYU  
RAMANBHAI AMIN  
Date: 2020.05.22  
13:31:52 +05'30'

**Chirayu Amin**  
**Chairman and CEO**

Place : Vadodara  
Date : 22nd May, 2020



**Statement of Standalone Audited Financial Results for the quarter and year ended 31st March, 2020.**

**Rs. in Crores**

	Particulars	Quarter Ended			Year Ended	
		31.03.2020 (Audited)	31.12.2019 (Unaudited)	31.03.2019 (Audited)	31.03.2020 (Audited)	31.03.2019 (Audited)
<b>1</b>	<b>Revenue from Operations</b>	<b>1,048.56</b>	1,052.36	848.70	<b>4,132.55</b>	3,660.27
<b>2</b>	<b>Other Income</b>	<b>131.01</b>	0.29	0.89	<b>134.75</b>	6.42
<b>3</b>	<b>Total Income</b>	<b>1,179.57</b>	1,052.65	849.59	<b>4,267.31</b>	3,666.69
<b>4</b>	<b>Expenses</b>					
	(a) Cost of Materials consumed	<b>273.30</b>	233.05	206.84	<b>978.13</b>	850.05
	(b) Purchase of stock-in-trade	<b>54.01</b>	50.04	51.33	<b>244.26</b>	230.45
	(c) Changes in Inventories of finished goods, Stock in trade and WIP	<b>(78.69)</b>	1.81	(42.14)	<b>(176.50)</b>	(80.41)
	(d) Employee benefits expense	<b>204.47</b>	204.62	178.92	<b>806.37</b>	684.45
	(e) Finance Costs	<b>6.97</b>	6.93	4.34	<b>25.19</b>	14.87
	(f) Depreciation & Amortization Expense	<b>36.35</b>	34.31	27.49	<b>135.67</b>	105.59
	(g) Other Expenses	<b>299.19</b>	241.72	300.73	<b>1,077.40</b>	1,097.06
	<b>Total Expenses</b>	<b>795.61</b>	772.48	727.51	<b>3,090.51</b>	2,902.06
<b>5</b>	<b>Profit before exceptional items and tax</b>	<b>383.96</b>	280.17	122.08	<b>1,176.79</b>	764.63
<b>6</b>	Less : Exceptional Expense	<b>10.00</b>	-	-	<b>10.00</b>	-
<b>7</b>	<b>Profit before tax</b>	<b>373.96</b>	280.17	122.08	<b>1,166.79</b>	764.63
<b>8</b>	<b>Tax Expense</b>					
	(i) Current Tax	<b>60.74</b>	48.97	18.52	<b>198.48</b>	157.52
	(ii) Short /(Excess) Tax Provision	<b>(1.09)</b>	-	(4.10)	<b>(1.09)</b>	(4.10)
<b>9</b>	<b>Net profit after tax for the period</b>	<b>314.30</b>	231.19	107.66	<b>969.40</b>	611.21
<b>10</b>	<b>Other Comprehensive Income</b>					
	(i) Items that will not be reclassified to profit / (loss)	<b>(7.31)</b>	2.35	(0.85)	<b>(11.30)</b>	(2.43)
	(ii) Income tax relating to items that will not be reclassified to profit / (loss)	<b>1.28</b>	(0.41)	0.18	<b>1.98</b>	0.52
<b>11</b>	<b>Total Comprehensive Income for the period</b>	<b>308.27</b>	233.14	106.99	<b>960.08</b>	609.30
<b>12</b>	Earnings per share - Basic & Diluted (in Rs.)	<b>16.67</b>	12.26	5.71	<b>51.42</b>	32.42
<b>13</b>	Paid up Equity Share Capital (Face Value of Rs 2/- each)	<b>37.70</b>	37.70	37.70	<b>37.70</b>	37.70
<b>14</b>	Other Equity				<b>3,308.32</b>	2,674.71
<b>15</b>	Networth (11 +12)				<b>3,346.02</b>	2,712.41
<b>16</b>	Debt Equity Ratio				<b>0.50</b>	0.39
<b>17</b>	Debt Service Coverage Ratio				<b>3.87</b>	10.38
<b>18</b>	Interest Service Coverage Ratio				<b>11.00</b>	10.38



**Notes :**

1 The above standalone results, have been audited by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.

2 As additional information to investors, the Research and Development Expenses are provided here under:

**Rs. in Crores**

Particulars	Quarter Ended			Year Ended	
	31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019
Research and Development	183.49	122.96	92.58	573.67	462.26

3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.

4 Asset cover available : - N.A. as unsecured non-convertible debentures were issued.

5 Next due date for payment of interest on unsecured non-convertible debentures is as follows, no principal amount is due till 31st March, 2021.

**Rs. in Crores**

Particulars	Due date	Interest
Tranche I	3 <sup>rd</sup> December, 2020	13.28
Tranche II	14 <sup>th</sup> December, 2020	18.00
Tranche III	19 <sup>th</sup> March, 2021	12.56

6 Previous due date for payment of interest on unsecured non-convertible debentures is as follows, no principal amount was due. Interest have been paid on the due dates.

Particulars	Due date	Interest
Tranche I	9 <sup>th</sup> December, 2019	13.22
Tranche II	14 <sup>th</sup> December, 2019	18.00
Tranche III	19 <sup>th</sup> March, 2020	12.56

7 The Company is rated by leading credit agency CRISIL. The rating "AA+/Stable" and "CRISIL A1+" has been assigned for long term and short term facility respectively.

8 Debenture Redemption Reserve Rs. 83.33 Crores is included in Other Equity (point no 14).

9 Ratios:

a) Debt to Equity: Debt / Net Worth

Debt : Total Debt ( Short term + Long term)

Net worth : Share Capital + Reserves & Surplus

b) Debt Service Coverage Ratio: EBIT / (Interest on term & working capital debt + Principal repayments of Long term (EBIT : Profit before Taxes + Interest)

c) Interest Service Coverage Ratio : EBIT / Interest

10 Effective 1st April, 2019, the Company has adopted Ind As 116 Leases using the modified retrospective approach. This has resulted in recognizing lease liability and equal amount of right of use assets as on 1st April, 2019. The adoption of the standard did not have any material impact on the financial results.

11 The Board of Directors had at their meeting on 6th March, 2020 declared Interim Dividend of Rs. 7/- (350%) per equity share and an additional Special Dividend of Rs. 3/- (150%) per equity share aggregating to total Interim Dividend of Rs. 10/- (500%) per equity share having face value of Rs. 2/- each for the financial year 2019-20 as against the Final Dividend of Rs. 5.50 (275%) per equity share for the financial year 2018-19. The same has been paid on 20th March, 2020 to the equity shareholders of the Company whose names appear in the Register of Members on 17th March, 2020, being the Record Date fixed for the purpose.

12 Exceptional items relates to compensation to National Green Tribunal Rs. 10 Crs.

13 As assessed by the management, Impact of Covid 19 on the financial statements of the Company is likely to be modest and for short term. Management does not foresee any medium to long term risk in company's ability to continue as going concern.

14 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / period.

**For Alembic Pharmaceuticals Limited**

CHIRAYU  
RAMANBHAI AMIN  
AI AMIN

Digitally signed by  
CHIRAYU  
RAMANBHAI AMIN  
Date: 2020.05.22  
13:32:12 +05'30'

Place : Vadodara  
Date : 22nd May, 2020

**Chirayu Amin**  
**Chairman and CEO**

Visit us at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com)



**Alembic Pharmaceuticals Limited**

**Statement of Assets and Liabilities - Standalone**

**Rs. in Crores**

Particulars		As at 31st March, 2020 (Audited)	As at 31st March, 2019 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Property, plant and equipment	<b>1,268.11</b>	1,077.09
	(b) Capital work-in-progress	<b>1,569.98</b>	1,106.89
	(c) Investment Property	<b>8.35</b>	8.35
	(d) Non-current investments	<b>833.25</b>	506.39
	(e) Other non-current assets	<b>47.71</b>	14.31
<b>2</b>	<b>Current assets</b>		
	(a) Inventories	<b>1,073.18</b>	891.41
	(b) Financial Assets		
	- Trade receivables	<b>784.11</b>	539.75
	- Cash and cash equivalents	<b>28.22</b>	144.25
	- Bank balances other than cash and cash equivalents	<b>8.91</b>	6.55
	- Others financial assets	<b>8.49</b>	8.95
	- Current Tax Assets (Net)	<b>8.12</b>	6.74
	- Other current assets	<b>240.33</b>	238.35
	<b>TOTAL - ASSETS</b>	<b>5,878.77</b>	4,549.03
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
	(a) Equity Share capital	<b>37.70</b>	37.70
	(b) Other Equity	<b>3,308.32</b>	2,674.71
<b>2</b>	<b>Non-current liabilities</b>		
	(a) Financial liabilities		
	- Borrowings	<b>886.99</b>	499.30
	- Others	<b>73.30</b>	-
	(b) Provisions	<b>73.21</b>	51.33
	(c) Deferred tax liabilities (net)	<b>45.76</b>	45.27
<b>3</b>	<b>Current liabilities</b>		
	(a) Financial liabilities		
	- Borrowings	<b>800.04</b>	359.98
	- Trade payables		
	A) Due to Micro and Small Enterprises	<b>6.72</b>	4.76
	B) Due to other than Micro and Small Enterprises	<b>386.45</b>	467.99
	- Other financial liabilities	<b>121.35</b>	290.97
	(b) Other current liabilities	<b>100.77</b>	84.65
	(c) Provisions	<b>38.17</b>	32.37
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>5,878.77</b>	4,549.03

**For Alembic Pharmaceuticals Limited**

CHIRAYU  
RAMANBHAI  
AMIN

Digitally signed by  
CHIRAYU RAMANBHAI  
AMIN  
Date: 2020.05.22  
13:32:35 +05'30'

**Chirayu Amin**  
**Chairman and CEO**

Place : Vadodara  
Date : 22nd May, 2020

Visit us at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com)



Standalone Cash Flow Statement for the year ended 31st March, 2020.

Particulars	Rs. In Crores	
	For the year ended 31st March, 2020 (Audited)	For the year ended 31st March, 2019 (Audited)
<b>A CASH FLOW FROM OPERATING ACTIVITIES:</b>		
Net Profit before tax after exceptional item	1,166.79	764.63
Adjustments for:		
Depreciation and amortisation	135.67	105.59
Interest charged	25.19	14.87
Interest Income	(1.58)	(1.43)
Dividend Income /Gain on Sale of Investments	(130.55)	(0.00)
Unrealised foreign exchange gain (net)	16.13	(23.83)
Provision / write off for doubtful trade receivables	0.56	0.47
Sundry balances written off / written Back	(2.82)	(0.58)
Remeasurement of Defined benefit obligations	(11.30)	(2.43)
Loss/(Profit) on sale of Asset	(1.16)	(1.18)
<b>Operating Profit before change in working capital</b>	<b>1,196.92</b>	<b>856.11</b>
Working capital changes:		
(Increase) In Inventories	(181.78)	(221.48)
(Increase) / Decrease In Trade Receivables	(219.03)	96.87
(Increase) / Decrease In Other Assets	(1.52)	119.22
Increase In Trade Payables	(82.18)	(66.65)
Increase / (Decrease) In Other Liabilities	(3.55)	175.97
Increase In Provisions	27.67	6.45
<b>Cash generated from operations</b>	<b>736.54</b>	<b>966.49</b>
Direct taxes paid (Net of refunds)	(196.79)	(157.69)
<b>Net Cash inflow from Operating Activities (A)</b>	<b>539.75</b>	<b>808.80</b>
<b>B CASH FLOW FROM INVESTING ACTIVITIES:</b>		
Sales of Property, Plant & Equipments	0.60	1.28
Government assistance	-	17.15
Interest received	1.58	1.43
Dividend Income /Gain on Sale of Investments received	130.55	0.00
Purchase of property, plant & equipments, intangible assets and Capital Advance	(628.19)	(565.96)
Investment in Subsidiary	(326.86)	(207.50)
<b>Net Cash inflow from Investing Activities (B)</b>	<b>(822.31)</b>	<b>(753.59)</b>
<b>C CASH FLOW FROM FINANCING ACTIVITIES:</b>		
Proceeds from borrowings	378.02	586.60
Repayment of borrowings	(200.00)	(587.30)
Net increase / (decrease) in working capital demand loans	440.06	238.45
Payment of lease liabilities	(17.11)	-
Increase in Restricted Bank Balances other than Cash & Cash Equivalents	(0.02)	(0.38)
Dividends paid (including distribution tax)	(325.97)	(90.91)
Interest and other finance costs (including borrowing cost capitalised)	(108.85)	(66.80)
<b>Net Cash inflow from Financing Activities (C)</b>	<b>166.13</b>	<b>79.67</b>
<b>I Net (decrease)/increase in cash and cash equivalents (A+B+C)</b>	<b>(116.43)</b>	<b>134.87</b>



Particulars	For the year	For the year
	ended 31st March, 2020 (Audited)	ended 31st March, 2019 (Audited)
II. a) Cash and cash equivalents at the beginning of the Year	144.25	9.45
b) Effect of exchange differences on restatement of foreign currency cash and cash equivalents	0.41	(0.07)
III. Cash and cash equivalents at the end of the Year (I+II)	<u>28.22</u>	<u>144.25</u>
IV. Cash and cash equivalents at the end of the Year		
Balances with Banks	27.88	144.03
Cash on hand	0.34	0.22
Cash and cash equivalents	<u>28.22</u>	<u>144.25</u>

**For Alembic Pharmaceuticals Limited**

CHIRAYU  
RAMANBHAI  
AMIN

Digitally signed by  
CHIRAYU RAMANBHAI  
AMIN  
Date: 2020.05.22  
13:33:02 +05'30'

Place : Vadodara  
Date : 22nd May, 2020

**Chirayu Amin**  
**Chairman and CEO**



# F-7 Laxmi Mills  
Shakti Mills Lane (Off Dr E Moses Rd)  
Mahalaxmi Mumbai 400 011 India  
Tel : 91 22 2493 2502 / 6655 1770  
Fax : 91 22 6655 1774  
Grams : VERIFY  
www.KSAiyar.com  
Mail@KSAiyar.com

## INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Alembic Pharmaceuticals Limited (Holding Company)

Report on the Audit of Consolidated Financial Results

### Opinion

We have audited the accompanying consolidated annual financial results of Alembic Pharmaceuticals Limited (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), its associates and jointly controlled entities for the year ended 31/03/2020, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements /financial results/ financial information of the subsidiaries, associates and jointly controlled entities, the aforesaid consolidated financial results:

(i) include the annual financial results of the following entities

#### Subsidiaries

1. Alembic Global Holdings SA.
2. Aleor Dermaceuticals Limited.
3. Alembic Pharmaceuticals Inc.
4. Orit LLC USA (Subsidiary of Alembic Pharmaceuticals Inc.)
5. Okner LLC USA (Subsidiary of Alembic Pharmaceuticals Inc.)
6. Alembic Pharmaceuticals Australia Pty Ltd. (Subsidiary of Alembic Global Holdings SA)
7. Alembic Pharmaceuticals Europe Limited. (Subsidiary of Alembic Global Holdings SA)
8. Alnova Pharmaceuticals SA. (Subsidiary of Alembic Global Holdings SA)
9. Alembic Pharmaceuticals Canada Limited. (Subsidiary of Alembic Global Holdings SA)
10. Genius LLC. (Subsidiary of Alembic Global Holdings SA)

#### Associates

1. Incozen Therapeutics Private Limited
2. Rhizen Pharmaceuticals SA



3. Dahlia Therapeutics SA (Subsidiary of Rhizen Pharmaceuticals SA)
4. Rhizen Pharmaceuticals Inc. (Subsidiary of Rhizen Pharmaceuticals SA)

Joint Venture

**1. Alembic Mami SPA**

(ii) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(iii) give a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Group for the year ended on 31/03/2020.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group, its associates and jointly controlled entities in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

**Board of Directors' Responsibilities for the Consolidated Financial Results**

These Consolidated financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group including its associates and jointly controlled entities in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and jointly controlled entities and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial



controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for assessing the ability of the Group and its associates and jointly controlled entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities is responsible for overseeing the financial reporting process of the Group and of its associates and jointly controlled entities.

#### **Auditor's Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.



# K. S. AIYAR & CO

CHARTERED ACCOUNTANTS

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associates and jointly controlled entities to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.



**Other Matters**

- (1) Re: Subsidiary Company, i.e., Aleor Dermaceuticals Limited. (Aleor)

Aleor's auditors have modified their audit opinion in financial statements for the year ended on 31<sup>st</sup> March, 2020 regarding the fact that Aleor has measured its financial liability of Non-convertible Redeemable Debentures (NCRD) issued to the Holding Company is valued at cost and is not at amortised cost as mandated by Ind AS 109-Financial Instruments. Had the NCRD been measured at Amortized Cost,

(a) the borrowing cost for the year to be included in the Property, plant and equipment (PPE), Intangible assets and qualifying asset Capital Work-in Progress and Intangible assets under development would have been higher by Rs.49.71 Crores (PY Rs.40.35 Crores)

(b) the borrowing costs for the year to be recognized as expense would be higher by Rs.16.14 Crores (PY Rs. Nil) on account of borrowing costs attributable to Property, plant and equipment and Intangible assets capitalized during the year.

As a result of the above, the amount of Property, plant and equipment, Intangible assets and qualifying assets of Capital work in progress and Intangible assets under development as at 31<sup>st</sup> March, 2020 would be higher by 111.34 Crores (PY 61.63 Crores) and the corresponding financial liability of NCRD would have been higher by Rs.127.48 Crores.

Corresponding interest income up to 31<sup>st</sup> March, 2020 of Rs. 127.48 Crores (PY 61.63 Crores) has not been recognized by the Holding Company (Alembic Pharmaceuticals Limited - APL) and is considered as contingent assets. The said NCRD have been carried at cost in separate financial statements of APL as per Ind AS 27.

On consolidation of financial statements (a) the said investment by APL and Financial liability of Aleor and (b) borrowing cost of Aleor and interest income of APL gets eliminated. Therefore it does not have any financial impact on the Group's Consolidated Financial statements.

2. (A) The consolidated Financial Results include the audited Financial Results of 10 subsidiaries whose Financial Statements/Financial Results/ financial information reflect total assets of Rs.1901.79 Crores as at 31/03/2020 , total revenue of Rs. 721.31 Crores and Rs.2211.69 Crores and total net profit after tax of Rs. 54.85 Crores and net loss after tax of Rs.27.32 Crores and total comprehensive income of Rs. 54.81 Crores and total comprehensive loss of Rs.27.45 Crores, for the quarter ended 31/03/2020 and for the period from 01/04/2019 to 31/03/2020 respectively and cash flows (net outflow) of Rs.23.00 Crores for the period from 01/04/2019 to 31/03/2020, as considered in the consolidated Financial Results, which have been audited by their respective independent auditors. The independent auditors' reports on financial statements/ Financial Results/financial information of these entities have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and



# K. S. AIYAR & CO

CHARTERED ACCOUNTANTS

disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.


(B) The consolidated Financial Results include the Group's share of net loss of Rs.0.07 Crores and net profit after tax of Rs.0.50 Crores and total comprehensive loss of Rs.0.07 Crores and total comprehensive income of Rs.0.05 Crores for the quarter ended 31/03/2020, and for the period from 01/04/2019 to 31/03/2020, respectively, as considered in the consolidated Financial Results, which have been audited by their respective independent auditors. The independent auditors' reports on financial statements/ Financial Results/financial information of these entities have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

(C) Audited financial statements for the year in respect of 1 Joint venture of the Group have not been received by the Group. No further share of loss in that joint venture is required to be borne by the Group as the entire Equity capital and loan given to it, is fully provided for, pending formal legal process for dis-association which is still to be initiated by the Group.

Our opinion on the consolidated Financial Results is not modified in respect of the above two matters.

The Financial Results include the results for the quarter ended 31/03/2020 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For K.S.Aiyar & Co.  
Chartered Accountants  
Firm's Registration No. 100186W



Rajesh S. Joshi  
Partner  
Membership No. 038526  
UDIN: **20038526AAAABB8910**  
Place of signature: Mumbai  
Date: 22/05/2020



# F-7 Laxmi Mills  
Shakti Mills Lane (Off Dr E Moses Rd)  
Mahalaxmi Mumbai 400 011 India  
Tel : 91 22 2493 2502 / 6655 1770  
Fax : 91 22 6655 1774  
Grams : VERIFY  
www.KSAiyar.com  
Mail@KSAiyar.com

**Independent Auditor's Report on Audited standalone Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**INDEPENDENT AUDITOR'S REPORT  
TO THE BOARD OF DIRECTORS OF ALEMBIC PHARMACEUTICALS LIMITED  
VADODARA**

**Report on the audit of the Standalone Financial Results**

**Opinion**

We have audited the accompanying quarterly standalone financial results of Alembic Pharmaceuticals Limited (the company) for the quarter ended on 31/03/2020 (which is derived as a balancing figures of the difference between audited figures in respect of the financial year ended on 31/03/2020 and the published unaudited year to date figures up to the third quarter of the current financial year ended on 31/12/2019 which were subject to limited review by us) and the year to date results for the period from 01/04/2019 to 31/03/2020 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended 31/03/2020 as well as the year to date results for the period from 01/04/2019 to 31/03/2020.



**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Management's Responsibilities for the Standalone Financial Results**

These standalone quarterly financial results (which is derived as a balancing figures of the difference between audited figures in respect of the financial year ended on 31/03/2020 and the published unaudited year to date figures up to the third quarter of the current financial year ended on 31/12/2019 which were subject to limited review) as well as the year to date standalone financial results have been prepared on the basis of the audited annual financial statements for the year ended on 31/03/2020. The Company's Board of Directors is responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.



The Board of Directors is also responsible for overseeing the Company's financial reporting process.

**Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.




# K. S. AIYAR & CO

CHARTERED ACCOUNTANTS

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For K.S.Aiyar & Co.  
Chartered Accountants  
Firm's Registration No. 100186W



Rajesh S. Joshi  
Partner,  
Membership Number 038526

UDIN: **20038526AAAABA9481**

Place of signature: Mumbai  
Date: 22/05/2020